These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 32587078)

  • 1. Overview of treatments used in transthyretin-related hereditary amyloidosis: a systematic review.
    Cristóbal Gutiérrez H; Pelayo-Negro AL; Gómez Gómez D; Martín Vega MÁ; Valero Domínguez M
    Eur J Hosp Pharm; 2020 Jul; 27(4):194-201. PubMed ID: 32587078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience of patisiran with transthyretin stabilizers in patients with hereditary transthyretin-mediated amyloidosis.
    Lin H; Merkel M; Hale C; Marantz JL
    Neurodegener Dis Manag; 2020 Oct; 10(5):289-300. PubMed ID: 32519928
    [No Abstract]   [Full Text] [Related]  

  • 3. A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.
    Benbrahim M; Norman K; Sanchorawala V; Siddiqi OK; Hughes D
    J Cardiovasc Pharmacol; 2021 May; 77(5):544-548. PubMed ID: 33657048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of hereditary and acquired forms of transthyretin amyloidosis in the era of personalized medicine: the role of randomized controlled trials.
    Buxbaum JN
    Amyloid; 2019 Jun; 26(2):55-65. PubMed ID: 30907141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent progress in the understanding and treatment of transthyretin amyloidosis.
    Sekijima Y
    J Clin Pharm Ther; 2014 Jun; 39(3):225-33. PubMed ID: 24749898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies.
    Adams D; Cauquil C; Labeyrie C; Beaudonnet G; Algalarrondo V; Théaudin M
    Expert Opin Pharmacother; 2016; 17(6):791-802. PubMed ID: 26800456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Planté-Bordeneuve V; Lin H; Gollob J; Agarwal S; Betts M; Fahrbach K; Chitnis M; Polydefkis M
    Expert Opin Pharmacother; 2019 Mar; 20(4):473-481. PubMed ID: 30489166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical diversity, diagnosis and treatment of hereditary amyloid neuropathy].
    Sekijima Y
    Rinsho Shinkeigaku; 2014; 54(12):953-6. PubMed ID: 25672679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the treatment of hereditary transthyretin amyloidosis: A review.
    Gertz MA; Mauermann ML; Grogan M; Coelho T
    Brain Behav; 2019 Sep; 9(9):e01371. PubMed ID: 31368669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of cardiac transthyretin amyloidosis: an update.
    Emdin M; Aimo A; Rapezzi C; Fontana M; Perfetto F; Seferović PM; Barison A; Castiglione V; Vergaro G; Giannoni A; Passino C; Merlini G
    Eur Heart J; 2019 Dec; 40(45):3699-3706. PubMed ID: 31111153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Specific pharmacological treatment guide for transthyretin amyloid cardiomyopathy, 2021].
    Villanueva E; Carretero M; Aguirre MA; Negro A; Belziti CA; Posadas-Martínez ML; Nucifora EM; Baratta S; Costabel JP; Higa C; Rivas C; Fernández A; Quiroga A; Dumont CA; Volberg VI; Streitenberg GM; Perez de Arenaza D
    Medicina (B Aires); 2022; 82(2):275-288. PubMed ID: 35417392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of clinical heterogeneity on conducting network meta-analyses in transthyretin amyloidosis with polyneuropathy.
    Samjoo IA; Salvo EM; Tran D; Amass L; Stewart M; Cameron C
    Curr Med Res Opin; 2020 May; 36(5):799-808. PubMed ID: 32011182
    [No Abstract]   [Full Text] [Related]  

  • 14. The use of diflunisal for transthyretin cardiac amyloidosis: a review.
    Ibrahim M; Saint Croix GR; Lacy S; Fattouh M; Barillas-Lara MI; Behrooz L; Mechanic O
    Heart Fail Rev; 2022 Mar; 27(2):517-524. PubMed ID: 34272629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Newly developed drug therapies for familial amyloid polyneuropathy: diflunisal and tafamidis].
    Sekijima Y
    Brain Nerve; 2014 Jul; 66(7):773-81. PubMed ID: 24998822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis.
    Coelho T; Adams D; Conceição I; Waddington-Cruz M; Schmidt HH; Buades J; Campistol J; Berk JL; Polydefkis M; Wang JJ; Chen J; Sweetser MT; Gollob J; Suhr OB
    Orphanet J Rare Dis; 2020 Jul; 15(1):179. PubMed ID: 32641071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of liver transplantation and tafamidis in hereditary transthyretin amyloidosis caused by transthyretin Leu55Pro mutation: a case report.
    Kon T; Misumi Y; Nishijima H; Honda M; Suzuki C; Baba M; Inomata Y; Obayashi K; Ando Y; Tomiyama M
    Amyloid; 2015; 22(3):203-4. PubMed ID: 26123280
    [No Abstract]   [Full Text] [Related]  

  • 18. Amyloid Polyneuropathy and Myocardial Amyloidosis 10 Years after Domino Liver Transplantation from a Patient with a Transthyretin Ser50Arg Mutation.
    Matsushima M; Yabe I; Tsuda M; Sakakibara M; Shimamura T; Sasaki H
    Intern Med; 2017 Dec; 56(23):3231-3235. PubMed ID: 28943540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current approaches for treatment of hereditary transthyretin amyloidosis (ATTR)].
    Zibert A; Hüsing-Kabar A; Schmidt H
    Dtsch Med Wochenschr; 2019 Oct; 144(20):1438-1443. PubMed ID: 31594020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Ultrastructure of Tissue Damage by Amyloid Fibrils.
    Koike H; Katsuno M
    Molecules; 2021 Jul; 26(15):. PubMed ID: 34361762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.